中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2015年
7期
392-396
,共5页
常树建%石鑫%徐振宇%刘劝
常樹建%石鑫%徐振宇%劉勸
상수건%석흠%서진우%류권
胃肠道恶性淋巴瘤%5年生存率%TNM%Lugano
胃腸道噁性淋巴瘤%5年生存率%TNM%Lugano
위장도악성림파류%5년생존솔%TNM%Lugano
gastrointestinal lymphoma%5-year survival rate%TNM%Lugano
目的:比较TNM与Lugano分期系统在预测原发性胃肠道恶性淋巴瘤患者5年生存率中的价值。方法:收集2001年2月至2013年8月手术治疗的原发性胃肠道恶性淋巴瘤患者73例。所有患者分别使用TNM及Lugano系统进行分期。5年生存率为生存比较的主要指标,Kaplan-Meier法绘制生存曲线,并行Log-rank检验。Cox回归分析方法检验不同临床因素对患者生存的影响。结果:本组患者中位随访时间42.4(1.3~158.6)个月,5年生存率77.82%。使用TNM系统分期时,Ⅰ、Ⅱ、Ⅲ期和Ⅳ期患者的5年生存率分别为100.0%、90.0%、67.4%和22.2%(χ2=17.7956,P=0.0005)。使用Lugano分期时,Ⅰ、Ⅱ、ⅡE期和Ⅳ期患者的5年生存率分别为100.0%、100.0%、70.7%和46.2%(χ2=15.6776,P=0.0013)。Cox分析提示肿瘤浸润深度(P=0.0181)和远处转移(P=0.003)是原发性胃肠道恶性淋巴瘤患者生存的独立预后因素。结论:TNM分期较Lugano分期可以更好地预测原发性胃肠道恶性淋巴瘤患者的5年生存率。
目的:比較TNM與Lugano分期繫統在預測原髮性胃腸道噁性淋巴瘤患者5年生存率中的價值。方法:收集2001年2月至2013年8月手術治療的原髮性胃腸道噁性淋巴瘤患者73例。所有患者分彆使用TNM及Lugano繫統進行分期。5年生存率為生存比較的主要指標,Kaplan-Meier法繪製生存麯線,併行Log-rank檢驗。Cox迴歸分析方法檢驗不同臨床因素對患者生存的影響。結果:本組患者中位隨訪時間42.4(1.3~158.6)箇月,5年生存率77.82%。使用TNM繫統分期時,Ⅰ、Ⅱ、Ⅲ期和Ⅳ期患者的5年生存率分彆為100.0%、90.0%、67.4%和22.2%(χ2=17.7956,P=0.0005)。使用Lugano分期時,Ⅰ、Ⅱ、ⅡE期和Ⅳ期患者的5年生存率分彆為100.0%、100.0%、70.7%和46.2%(χ2=15.6776,P=0.0013)。Cox分析提示腫瘤浸潤深度(P=0.0181)和遠處轉移(P=0.003)是原髮性胃腸道噁性淋巴瘤患者生存的獨立預後因素。結論:TNM分期較Lugano分期可以更好地預測原髮性胃腸道噁性淋巴瘤患者的5年生存率。
목적:비교TNM여Lugano분기계통재예측원발성위장도악성림파류환자5년생존솔중적개치。방법:수집2001년2월지2013년8월수술치료적원발성위장도악성림파류환자73례。소유환자분별사용TNM급Lugano계통진행분기。5년생존솔위생존비교적주요지표,Kaplan-Meier법회제생존곡선,병행Log-rank검험。Cox회귀분석방법검험불동림상인소대환자생존적영향。결과:본조환자중위수방시간42.4(1.3~158.6)개월,5년생존솔77.82%。사용TNM계통분기시,Ⅰ、Ⅱ、Ⅲ기화Ⅳ기환자적5년생존솔분별위100.0%、90.0%、67.4%화22.2%(χ2=17.7956,P=0.0005)。사용Lugano분기시,Ⅰ、Ⅱ、ⅡE기화Ⅳ기환자적5년생존솔분별위100.0%、100.0%、70.7%화46.2%(χ2=15.6776,P=0.0013)。Cox분석제시종류침윤심도(P=0.0181)화원처전이(P=0.003)시원발성위장도악성림파류환자생존적독립예후인소。결론:TNM분기교Lugano분기가이경호지예측원발성위장도악성림파류환자적5년생존솔。
Objective:To assess the survival-predictive value of TNM and Lugano staging systems in patients with primary gastro-intestinal lymphoma (PGL). Methods:A total of 73 patients with PGL were recruited from February 2001 to August 2013. All patients were diagnosed according to the TNM and Lugano staging systems. Five-year survival rate was used as the major clinical outcome. Sur-vival curves were plotted using the Kaplan–Meier method and analyzed with the log-rank test. The prognostic value of different vari-ables for clinical outcomes was assessed using the Cox multiple regression model. Results:The median follow-up time of surviving pa-tients was 42.4 months (range:1.3-158.6 months). The estimated 5-year overall survival rate was 77.82%. When diagnosed with the TNM system, the 5-year survival rates in stagesⅠ,Ⅱ,Ⅲ, andⅣwere 100%, 90.0%, 67.4%, and 22.2%, respectively (χ2=17.7956, P=0.0005). When staged by the Lugano system, the 5-year survival rates in stagesⅠ,Ⅱ,ⅡE , andⅣwere 100%, 100%, 70.7%, and 46.2%, respectively (χ2=15.6776, P=0.0013). Cox analysis showed that the invasion depth (T) (P=0.0181) and metastasis (M) (P=0.0031) were covariates that were prognostically significant for the overall survival. Conclusion:The TNM staging system is more ac-curate than the Lugano system in predicting the 5-year survival rate of patients with PGL.